SAMD5 Inhibitors
Chemical inhibitors of SAMD5 can modulate its activity by engaging distinct signaling pathways in which this protein is involved. LY294002 and Wortmannin are both PI3K inhibitors that directly target the PI3K/AKT signaling pathway, a key route for regulating various cellular processes, including those associated with SAMD5. By inhibiting PI3K, these compounds disrupt the pathway, leading to reduced phosphorylation of AKT and subsequent decrease in the activity of SAMD5-related signaling events. U0126 and PD98059, as MEK inhibitors, attenuate the MAPK/ERK pathway by preventing the activation of MEK1/2, which ultimately limits the influence of SAMD5 within this cascade. SB203580, a p38 MAP kinase inhibitor, and SP600125, a JNK inhibitor, similarly alter the MAPK signaling pathways, potentially curtailing the functional contributions of SAMD5 in stress response and other cellular processes.
Further into the array of inhibitors, Rapamycin exerts its effect by inhibiting mTOR, thus influencing the mTOR signaling pathway and the role of SAMD5 within it. Bortezomib, by inhibiting the proteasome, prevents the degradation of various regulatory proteins, indirectly affecting the cell cycle and apoptosis processes where SAMD5 may be involved. Palbociclib takes a different approach by inhibiting CDK4/6, thereby stalling the cell cycle at the G1 to S phase transition, which is a critical control point for SAMD5's regulatory functions. The Src family kinase inhibitor Dasatinib disrupts specific kinase-mediated signaling pathways, which can reduce the activation of downstream effectors of SAMD5. Thapsigargin and Trichostatin A act through distinct mechanisms; Thapsigargin disturbs calcium homeostasis, implicating calcium-dependent signaling pathways, while Trichostatin A, an HDAC inhibitor, alters chromatin structure and gene expression, affecting pathways in which SAMD5 plays a role without altering its expression. Each of these inhibitors, through their specific molecular targets, can modulate the activity and influence of SAMD5 within numerous cellular signaling networks.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor which can inhibit SAMD5 by disrupting the PI3K/AKT signaling pathway, as SAMD5 is known to be involved in this pathway. The inhibition of PI3K leads to a decrease in AKT phosphorylation, thereby reducing the activity of downstream effectors that require SAMD5. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. SAMD5 has been implicated in the MAPK signaling pathway; thus, inhibiting MEK can attenuate ERK activation and subsequent signaling events that involve SAMD5. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. Inhibition of p38 can limit the activation of downstream targets that may interact with SAMD5, thus functionally inhibiting SAMD5's role in stress response signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathways. SAMD5's function could be influenced by the JNK pathway, and by inhibiting JNK, the activity of SAMD5 in these pathways can be reduced. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor and by inhibiting mTOR, it can inhibit SAMD5 by disrupting the mTOR signaling pathway in which SAMD5 has been implicated. The inhibition of mTOR leads to decreased activity of downstream proteins that are involved in cell growth and proliferation where SAMD5 may play a role. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can inhibit SAMD5 by preventing the degradation of regulatory proteins that control cell cycle and apoptosis, processes in which SAMD5 might be involved. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor that can inhibit SAMD5 by stalling the cell cycle, which is a process where SAMD5 is implicated, particularly in the regulation of G1 to S phase progression. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor which can inhibit SAMD5 by hampering the Src family kinase-mediated signaling pathways, potentially reducing the activation of downstream effectors that interact with SAMD5. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that can disrupt calcium homeostasis and thereby inhibit SAMD5 by affecting the calcium-dependent signaling pathways in which SAMD5 is involved. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an HDAC inhibitor that can inhibit SAMD5 by altering chromatin structure and gene expression, which in turn can affect the pathways involving SAMD5 without affecting its expression levels. | ||||||